



## Email Communication from EpiphanyRx: Update: Humira® to be Removed from Formularies Effective June 1

Dear valued client,

Over the past year, several biosimilars of Humira® have come to market, designed to have the same clinical effect to those of the reference drug. These have introduced many lower cost options for clients and members.

EpiphanyRx is committed to making medications more affordable. We support the availability of biosimilars to reduce costs within the pharmacy benefit. As such, **on June 1, 2024, EpiphanyRx will remove Humira from our formulary**, further demonstrating our overall lowest-net-cost formulary management strategy.

You may recall we previously added three Humira biosimilars to our formulary as of October 1, 2023: the low wholesale acquisition cost (WAC) Adalimumab-adaz, Adalimumab-fkjp, and Hadlima™. We believe it is the right time to support further transition to a low WAC / low rebate biosimilar product to enable you and your members to capture the savings available.

### Upcoming Actions:

Members currently on Humira therapy will need to transition to one of the on-formulary biosimilars by June 1, 2024 for their medication to be covered by their pharmacy benefit.

Efforts have begun to assist members in this formulary transition. Members currently using Humira will receive a letter communication in March. We are in communication with in-network specialty pharmacies to alert them to this forthcoming change in order for them to support members in obtaining a new prescription if necessary. A new prior authorization will not be required.

Should you have any questions regarding the above, please reach out to your Account Team.

Regards,

The EpiphanyRx Team

